Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 15/20 | 0.75 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341127 | 1.00 | STING1 (0.75) | STING1PDE3BPDE3APDE4APDE4B | |
| SCHEMBL29486908 | 1.00 | STING1 (0.75) | STING1PDE3BPDE3APDE4APDE4B | |
| SCHEMBL25063900 | 0.89 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL26351022 | 0.89 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL24649405 | 0.89 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL19954144 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL24467522 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21470181 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21498373 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17974376 | 0.86 | STING1 (1.00) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172325-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172325-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172325-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20090233882-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233882-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233882-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1957509-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062168-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233882-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | HRH2, P2RY4, P2RY11 | STING1 2133/4885PDE3B 9/4885PDE3A 7/4885 |
| US-20120172325-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | HRH2, P2RY4, P2RY11 | STING1 2133/4885PDE3B 9/4885PDE3A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.